8.0788

1.47% -0.1712

Grifols Sa Adr (GRFS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché GRFS Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$8.25

Aprire:

$8.19

Volume 24 ore:

164.78K

Relative Volume:

0.25

Capitalizzazione di mercato:

$5.51B

Reddito:

$8.62B

Utile/perdita netta:

$573.80M

Rapporto P/E:

11.43

EPS:

0.707

Flusso di cassa netto:

$680.05M

1 W Prestazione:

+2.51%

1M Prestazione:

+6.82%

6M Prestazione:

-13.52%

1 anno Prestazione:

-19.91%

Intervallo 1D:

$8.06

$8.20

Intervallo di 1 settimana:

$7.68

$8.38

Portata 52W:

$6.96

$10.23

Grifols Sa Adr Stock (GRFS) Company Profile

Nome

Grifols Sa Adr

Settore

Healthcare (1084)

Industria

Drug Manufacturers - General (20)

Telefono

Indirizzo

Dipendente

25,247

Cinguettio

Prossima data di guadagno

2026-08-24

Ultimi documenti SEC

GRFS's Discussions on Twitter

Compare GRFS vs LLY, JNJ, ABBV, MRK, NVS

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GRFS Grifols Sa Adr	8.09	5.61B	8.62B	573.80M	680.05M	0.707
LLY Lilly Eli Co	1,265.04	1.14T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	270.49	658.89B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	264.88	470.00B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	151.37	375.50B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	157.38	304.70B	54.66B	13.58B	16.05B	7.0171

Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-12	Ripresa	Morgan Stanley	Overweight
2024-03-12	Downgrade	Deutsche Bank	Hold → Sell
2023-04-12	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2023-03-03	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2023-02-16	Aggiornamento	Barclays	Underweight → Equal Weight
2023-01-18	Aggiornamento	Jefferies	Hold → Buy
2022-04-08	Iniziato	Morgan Stanley	Equal-Weight
2021-11-05	Downgrade	Deutsche Bank	Buy → Hold
2021-10-19	Downgrade	Barclays	Overweight → Underweight
2021-10-06	Aggiornamento	Citigroup	Neutral → Buy
2021-06-14	Aggiornamento	Deutsche Bank	Hold → Buy
2021-04-20	Iniziato	Deutsche Bank	Hold
2021-03-23	Aggiornamento	Credit Suisse	Neutral → Outperform
2021-03-11	Aggiornamento	HSBC Securities	Hold → Buy
2020-10-01	Aggiornamento	Citigroup	Sell → Neutral
2020-06-09	Downgrade	Citigroup	Neutral → Sell
2020-06-09	Aggiornamento	HSBC Securities	Reduce → Hold
2020-03-25	Downgrade	Citigroup	Buy → Neutral
2019-06-27	Aggiornamento	JP Morgan	Neutral → Overweight
2019-02-08	Downgrade	Berenberg	Buy → Hold
2018-10-11	Aggiornamento	Berenberg	Hold → Buy
2018-06-01	Iniziato	Barclays	Overweight
2017-10-31	Iniziato	Citigroup	Buy
2017-06-30	Downgrade	Goldman	Buy → Neutral
2017-04-06	Iniziato	BofA/Merrill	Buy
2017-01-03	Aggiornamento	JP Morgan	Neutral → Overweight
2016-02-09	Aggiornamento	Berenberg	Hold → Buy
2016-01-04	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2015-12-02	Downgrade	HSBC Securities	Buy → Hold
2015-11-20	Downgrade	Berenberg	Buy → Hold
2015-04-28	Downgrade	Berenberg	Buy → Hold

Mostra tutto

Grifols Sa Adr Borsa (GRFS) Ultime notizie

Aug 15, 2026

ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - tradingview.com

Aug 15, 2026

Aug 13, 2026

Grifols stock trades below $8 as investors weigh earnings outlook - Ad-hoc-news.de

Aug 13, 2026

Aug 10, 2026

Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK

Aug 10, 2026

Aug 02, 2026

Grifols ADRs Drop 4% to $7.87 as GRFS Nears Key Support at $7.48Insider Buying Alerts - Vinanet

Aug 02, 2026

Jul 29, 2026

Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 25, 2026

Jul 23, 2026

Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jul 23, 2026

Jul 22, 2026

[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

Jul 22, 2026

Jul 16, 2026

Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com - Investing.com UK

Jul 16, 2026

Jul 08, 2026

G0FB Forecast — Price Target — Prediction for 2027 - TradingView

Jul 08, 2026

Jul 04, 2026

GRFSGrifols SA ADR Options - Finviz

Jul 04, 2026

Jun 28, 2026

G0F Forecast — Price Target — Prediction for 2027 - TradingView

Jun 28, 2026

Grifols operations profile, Sunday focus on plasma and strategy - ad-hoc-news.de

Jun 28, 2026

Jun 26, 2026

A1C3HH Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Grifols, S.A. Class A Actuals & Estimates (BME:GRF) - TradingView

Jun 26, 2026

A1J1E2 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Grifols, S.A. Sponsored ADR Class B Actuals & Estimates (NASDAQ:GRFS) - TradingView

Jun 26, 2026

Jun 25, 2026

Grifols holds technical support, shares trade in a tight Nasdaq range - AD HOC NEWS

Jun 25, 2026

Jun 13, 2026

Grifols S.A. Stock (ES0171996087): IBEX 35 plasma specialist in focus after modest gain - Ad-hoc-news.de

Jun 13, 2026

Jun 11, 2026